Sunbelt Securities Inc. Raises Stock Position in Hims & Hers Health, Inc. $HIMS

Sunbelt Securities Inc. grew its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 5,444.7% in the first quarter, Holdings Channel.com reports. The fund owned 23,565 shares of the company’s stock after purchasing an additional 23,140 shares during the period. Sunbelt Securities Inc.’s holdings in Hims & Hers Health were worth $489,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. Vanguard Group Inc. raised its holdings in Hims & Hers Health by 7.2% during the fourth quarter. Vanguard Group Inc. now owns 20,925,666 shares of the company’s stock worth $679,456,000 after purchasing an additional 1,407,651 shares during the last quarter. Munich Reinsurance Co Stock Corp in Munich acquired a new stake in Hims & Hers Health in the fourth quarter valued at $11,187,000. Cunning Capital Partners LP acquired a new stake in Hims & Hers Health in the fourth quarter valued at $1,110,000. Virtu Financial LLC purchased a new position in shares of Hims & Hers Health in the fourth quarter valued at $1,937,000. Finally, Norges Bank purchased a new position in shares of Hims & Hers Health in the fourth quarter valued at $62,153,000. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Insider Transactions at Hims & Hers Health

In related news, CFO Oluyemi Okupe sold 18,197 shares of the business’s stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $34.03, for a total value of $619,243.91. Following the completion of the transaction, the chief financial officer owned 284,321 shares of the company’s stock, valued at approximately $9,675,443.63. The trade was a 6.02% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director David B. Wells bought 48,400 shares of Hims & Hers Health stock in a transaction on Tuesday, May 26th. The stock was purchased at an average price of $24.23 per share, for a total transaction of $1,172,732.00. Following the completion of the acquisition, the director owned 224,417 shares in the company, valued at $5,437,623.91. This represents a 27.50% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have sold a total of 83,126 shares of company stock worth $2,711,339 in the last ninety days. Company insiders own 11.76% of the company’s stock.

Trending Headlines about Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: One bullish analysis argues that Hims & Hers remains undervalued, citing projected revenue growth, approximately 73% gross margins, accelerating subscriber additions, GLP-1 and peptide demand, international expansion, and the Novo Nordisk partnership. The thesis suggests substantial long-term upside if the company sustains growth despite the regulatory controversy. Hims & Hers Health: Still an Undervalued Company With Tremendous Upside
• Neutral Sentiment: Several law firms, including SBS Law, Kaplan Fox, Howard G. Smith, and Holzer & Holzer, announced investigations into possible securities-law violations. These announcements are typically investor-solicitation notices and do not establish wrongdoing, but they raise the possibility of shareholder litigation and additional disclosure obligations. SBS Law Investigation
• Negative Sentiment: The FTC alleges Hims & Hers shared customers’ health information with advertising platforms including Meta and Snap, failed to clearly disclose prescription charges, and used potentially deceptive billing and privacy practices. The lawsuit could lead to penalties, higher compliance expenses, tighter restrictions on marketing, and damage to consumer trust. Media coverage of the action contributed to a sharp decline in the shares and remains the principal near-term risk for HIMS. FTC Sues Hims & Hers

Wall Street Analyst Weigh In

HIMS has been the subject of several research reports. Truist Financial lifted their price target on Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research note on Friday, July 24th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a $25.00 price objective on shares of Hims & Hers Health in a research note on Tuesday, May 5th. Jefferies Financial Group set a $24.50 target price on shares of Hims & Hers Health in a report on Tuesday, May 12th. UBS Group set a $23.00 target price on shares of Hims & Hers Health in a research report on Friday, May 22nd. Finally, Canaccord Genuity Group upped their price target on shares of Hims & Hers Health from $32.00 to $40.00 and gave the company a “buy” rating in a report on Wednesday, July 1st. Four research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $31.43.

Hims & Hers Health Stock Performance

Hims & Hers Health stock opened at $27.79 on Friday. Hims & Hers Health, Inc. has a fifty-two week low of $13.74 and a fifty-two week high of $70.43. The company has a market capitalization of $6.43 billion, a price-to-earnings ratio of -308.74, a PEG ratio of 76.10 and a beta of 2.35. The stock has a fifty day moving average of $31.23 and a two-hundred day moving average of $26.12. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.56 and a current ratio of 1.69.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.44). The company had revenue of $608.10 million during the quarter, compared to analysts’ expectations of $616.84 million. Hims & Hers Health had a negative net margin of 0.56% and a positive return on equity of 6.10%. The firm’s revenue was up 3.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.20 earnings per share. On average, analysts anticipate that Hims & Hers Health, Inc. will post 0.03 EPS for the current fiscal year.

Hims & Hers Health Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.